Aligos therapeutics initiates dosing with its small interfering rna (sirna) drug candidate, alg-125755, in subjects with chronic hepatitis b (chb)

Single and multiple ascending doses to be evaluated in chb subjects throughout 2023 single and multiple ascending doses to be evaluated in chb subjects throughout 2023

ALGS Ratings Summary

ALGS Quant Ranking